Open AccessHematopoietic growth factors: Personalization of risks and benefits
Author(s) -
Puhalla Shan,
Bhattacharya Saveri,
Davidson Nancy E.
Publication year - 2012
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2012.03.001
Subject(s) - erythropoietin , medicine , haematopoiesis , anemia , bone marrow , granulocyte colony stimulating factor , intensive care medicine , depression (economics) , oncology , stem cell , chemotherapy , biology , genetics , macroeconomics , economics
A common side effect of cancer treatment is bone marrow suppression. The resulting myelosuppression and anemia can cause significant morbidity and mortality for patients. Agents such as granulocyte colony stimulating factors (GCSF) and erythropoietin stimulating agents (ESAs) may be helpful to ameliorate this depression of blood counts; however these agents have risks which also need to be carefully weighed.